Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Activist Investor Starboard Takes $1 Billion Stake In Pfizer
Pfizer CEO Bourla To Meet Activist Investor Starboard, Report Says
KEY TAKEAWAYS Pfizer CEO Albert Bourla reportedly is planning to meet with Starboard Value after the activist investor took a $1 billion stake in the struggling drugmaker.Bourla and at least one other director will hold discussions with Starboard next week,
Pfizer’s bondholders cheer news of activist investor Starboard’s $1 billion investment
Pfizer Inc.’s stock gained Monday after a report that activist investor Starboard Value has invested $1 billion in the drug company. Bondholders seem to like the news too.
Pfizer CEO plans to meet activist investor Starboard Value, FT reports
Pfizer CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday, citing people familiar with the matter.
1d
Former Pfizer chief pitches board on Starboard Value’s shake-up plan
Starboard has prepared a pitch deck about its turnaround plans for Pfizer but this has yet to be circulated to the drugmaker’s directors and investors, said two people familiar with the matter. But ...
2d
Pfizer Stock Slump: Will Starboard's Billion-Dollar Bet Spark Rebound?
Pfizer's stock has struggled due to declining demand for COVID-19 treatments, but activist investor Starboard's $1 billion ...
1d
on MSN
Why Pfizer Stock Popped on Monday
Pfizer ( PFE 3.18%) stock jumped 3.1% through 11:20 a.m. ET Monday morning in response to a Wall Street Journal article over ...
1d
Pfizer goes from hunter to hunted as Starboard circles
With one headline, Pfizer had gone from being a well-known hunter — spending heavily to buy rivals — to the hunted.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Albert Bourla
The Wall Street Journal
Pharma
Ian Read
Feedback